Theravance SVP uses shares to cover taxes

Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a routine tax-withholding share disposition tied to equity compensation.

Accepted by SEC EDGAR 05/22/2026 - 06:18 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Theravance Biopharma, Inc. senior vice president Rhonda Farnum reported a routine tax-withholding share disposition tied to equity compensation. On the vesting of previously granted restricted stock units, 5,678 Ordinary Shares were withheld at $16.55 per share to satisfy tax obligations. The shares were withheld by the company and did not involve any open-market transaction. After this non-market disposition, Farnum directly holds 245,771 Ordinary Shares, indicating she retains a substantial equity stake following the tax payment event.

Insider Trade Summary

Exercise Price or Tax Liability: 5,678 shares

Exercise Price or Tax Liability 1 txn

Insider Farnum Rhonda

Role SVP, COMM & MEDICAL AFFAIRS

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Ordinary Shares	5,678	$16.55	$94K

Holdings After Transaction: Ordinary Shares — 245,771 shares (Direct)

Holdings Before and After: Ordinary Shares, 251,449 to 245,771 shares (Direct)

Footnotes (1)

1. F1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

Key Figures

Shares withheld for taxes: 5,678 shares Withholding price: $16.55 per share Shares held after transaction: 245,771 shares +1 more

4 metrics

Shares withheld for taxes 5,678 shares Tax-withholding disposition on RSU vesting

Withholding price $16.55 per share Value used for tax-withholding shares

Shares held after transaction 245,771 shares Direct Ordinary Shares following disposition

Tax-withholding shares count 5,678 shares Reported in transactionSummary as taxWithholdingShares

Key Terms

restricted stock units, tax obligations, tax-withholding disposition, Ordinary Shares

4 terms

restricted stock units financial

"arising out of the vesting of previously granted restricted stock units"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

tax obligations financial

"Shares withheld to satisfy tax obligations arising out of the vesting"

tax-withholding disposition financial

"transaction_action: tax-withholding disposition"

A tax-withholding disposition is an event or transaction—such as selling or transferring securities, exercising options, or receiving compensation—that triggers a requirement to hold back part of the payment and remit it to tax authorities. It matters to investors because it reduces the cash they receive immediately and can change the timing and amount of taxable income, like a cashier taking a portion of your sale proceeds to pay taxes before you get the rest.

Ordinary Shares financial

"security_title: Ordinary Shares"

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Theravance Biopharma (TBPH) report for Rhonda Farnum?

Theravance Biopharma reported that SVP Rhonda Farnum had 5,678 Ordinary Shares withheld to cover taxes from vesting restricted stock units. This was a non-market transaction with the issuer, not an open-market buy or sell.

Was the Theravance Biopharma (TBPH) insider transaction an open-market sale?

No, the transaction was not an open-market sale. Shares were withheld by Theravance Biopharma to satisfy tax obligations triggered by vesting restricted stock units, meaning no shares were sold into the market in this event.

How many Theravance Biopharma (TBPH) shares were used for Rhonda Farnum’s tax withholding?

A total of 5,678 Ordinary Shares were withheld at $16.55 per share to satisfy Rhonda Farnum’s tax obligations arising from vesting restricted stock units, as disclosed in the Form 4 footnote.

How many Theravance Biopharma (TBPH) shares does Rhonda Farnum hold after the transaction?

Following the tax-withholding share disposition, Rhonda Farnum directly holds 245,771 Ordinary Shares of Theravance Biopharma, indicating she maintains a significant remaining equity position after the tax-related event.

What does a tax-withholding disposition mean for Theravance Biopharma (TBPH) insiders?

A tax-withholding disposition means the company withholds shares to pay taxes owed on vesting equity awards. For Theravance Biopharma insiders, it is a mechanical step tied to compensation, not a discretionary decision to buy or sell shares in the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Farnum Rhonda

(Last) (First) (Middle)

C/O THERAVANCE BIOPHARMA US, LLC

901 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Theravance Biopharma, Inc. [ TBPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, COMM & MEDICAL AFFAIRS

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/20/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	05/20/2026		F		5,678(1)	D	$16.55	245,771	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Shares withheld to satisfy tax obligations arising out of the vesting of previously granted restricted stock units. The share withholding transaction was with the issuer and did not involve an open market transaction.

	/s/ Brett A Grimaud, Attorney-in-Fact	05/22/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)